Comparing Liver Cancer Prevention Strategies in Japan and the US

Dr. Ryosuke Tateishi discussed the differences in liver cancer prevention strategies between Japan and the US at a recent medical conference. He noted that while Japan leads in hepatitis C management, the US offers valuable insights into addressing obesity-related liver disease.
Why it matters
Cross-border medical knowledge sharing is essential for improving global health outcomes as the primary causes of liver cancer shift from viral to metabolic factors.
In an interview with CancerNetwork® at The Liver Meeting® 2026, Ryosuke Tateishi, MD, PhD, FAASLD, of the University of Tokyo, discussed what clinicians in the US and Japan can learn from each other as the leading causes of hepatocellular carcinoma (HCC) shift from viral hepatitis to metabolic dysfunction.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in